What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?-Reference-Cited by-同舟云学术

What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?

Published:2018-11-10 Issue:32 Volume:36 Page:3183-3185
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Flowers Christopher R.¹,Ramsey Scott D.¹

Affiliation:

1. Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; and Scott D. Ramsey, Fred Hutchinson Cancer Research Center, Seattle, WA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.79.3570

Reference18 articles.

1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

2. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review;Regenerative Medicine;2022-03

2. A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients;Value in Health;2022-01

3. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?;Bulletin du Cancer;2021-12

4. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions;Drug Discovery Today;2021-02

5. Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications;Journal of Clinical Oncology;2020-02-01